Rigel Pharmaceuticals, Inc. (RIGL)
USD 17.03
(-3.54%)
USD 17.03
(-3.54%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 27.79 Million USD | 62.59% |
| 2022 | 17.09 Million USD | 46.42% |
| 2021 | 11.67 Million USD | 33.98% |
| 2020 | 8.71 Million USD | -36.81% |
| 2019 | 13.79 Million USD | 118.07% |
| 2018 | -76.32 Million USD | -100.82% |
| 2017 | -38 Million USD | -168.18% |
| 2016 | -14.17 Million USD | 61.69% |
| 2015 | -36.99 Million USD | -523.37% |
| 2014 | -5.93 Million USD | 71.55% |
| 2013 | -20.85 Million USD | 37.72% |
| 2012 | -33.48 Million USD | -79.7% |
| 2011 | -18.63 Million USD | -130.69% |
| 2010 | -8.07 Million USD | 36.77% |
| 2009 | -12.77 Million USD | 70.03% |
| 2008 | -42.61 Million USD | 0.27% |
| 2007 | -42.72 Million USD | 5.83% |
| 2006 | -45.37 Million USD | 39.16% |
| 2005 | -74.57 Million USD | -788.56% |
| 2004 | -8.39 Million USD | -37.01% |
| 2003 | -6.12 Million USD | 70.6% |
| 2002 | -20.83 Million USD | -411.39% |
| 2001 | -4.07 Million USD | 89.79% |
| 2000 | -39.91 Million USD | -2295.65% |
| 1999 | 1.81 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 24.27 Million USD | -30.49% |
| 2024 Q1 | 34.92 Million USD | 25.66% |
| 2023 Q4 | 27.79 Million USD | 80.66% |
| 2023 Q2 | 11.85 Million USD | -42.02% |
| 2023 Q3 | 15.38 Million USD | 29.76% |
| 2023 Q1 | 20.45 Million USD | 19.63% |
| 2023 FY | 27.79 Million USD | 62.59% |
| 2022 Q4 | 17.09 Million USD | 32.35% |
| 2022 FY | 17.09 Million USD | 46.42% |
| 2022 Q3 | 12.91 Million USD | 52.94% |
| 2022 Q2 | 8.44 Million USD | -37.28% |
| 2022 Q1 | 13.46 Million USD | 15.32% |
| 2021 FY | 11.67 Million USD | 33.98% |
| 2021 Q1 | 17.01 Million USD | 95.2% |
| 2021 Q2 | -49.88 Million USD | -393.29% |
| 2021 Q3 | 2.37 Million USD | 104.75% |
| 2021 Q4 | 11.67 Million USD | 392.2% |
| 2020 Q4 | 8.71 Million USD | 92.28% |
| 2020 Q1 | -10.31 Million USD | -174.77% |
| 2020 Q3 | 4.53 Million USD | -31.85% |
| 2020 Q2 | 6.65 Million USD | 164.49% |
| 2020 FY | 8.71 Million USD | -36.81% |
| 2019 Q1 | -42.99 Million USD | 43.67% |
| 2019 FY | 13.79 Million USD | 118.07% |
| 2019 Q3 | -870 Thousand USD | 93.85% |
| 2019 Q4 | 13.79 Million USD | 1685.17% |
| 2019 Q2 | -14.14 Million USD | 67.11% |
| 2018 Q3 | -61.48 Million USD | 5.52% |
| 2018 Q4 | -76.32 Million USD | -24.13% |
| 2018 FY | -76.32 Million USD | -100.82% |
| 2018 Q1 | -40.12 Million USD | -5.58% |
| 2018 Q2 | -65.07 Million USD | -62.19% |
| 2017 Q3 | -24.63 Million USD | 18.96% |
| 2017 FY | -38 Million USD | -168.18% |
| 2017 Q2 | -30.39 Million USD | 17.89% |
| 2017 Q1 | -37.01 Million USD | -156.88% |
| 2017 Q4 | -38 Million USD | -54.3% |
| 2016 FY | -14.17 Million USD | 61.69% |
| 2016 Q1 | -8.53 Million USD | 78.9% |
| 2016 Q3 | -21.71 Million USD | -8.83% |
| 2016 Q4 | -14.41 Million USD | 33.65% |
| 2016 Q2 | -19.95 Million USD | -133.8% |
| 2015 Q3 | -31.39 Million USD | -234.0% |
| 2015 Q4 | -40.45 Million USD | -28.85% |
| 2015 FY | -36.99 Million USD | -523.37% |
| 2015 Q1 | -34.13 Million USD | -475.19% |
| 2015 Q2 | -9.39 Million USD | 72.46% |
| 2014 FY | -5.93 Million USD | 71.55% |
| 2014 Q1 | -14.91 Million USD | 28.5% |
| 2014 Q4 | -5.93 Million USD | 53.69% |
| 2014 Q3 | -12.81 Million USD | 46.34% |
| 2014 Q2 | -23.88 Million USD | -60.17% |
| 2013 Q1 | -34.15 Million USD | -2.02% |
| 2013 FY | -20.85 Million USD | 37.72% |
| 2013 Q3 | -16.03 Million USD | 26.69% |
| 2013 Q4 | -20.85 Million USD | -30.09% |
| 2013 Q2 | -21.86 Million USD | 35.98% |
| 2012 FY | -33.48 Million USD | -79.7% |
| 2012 Q4 | -33.48 Million USD | -24.94% |
| 2012 Q3 | -26.8 Million USD | -2.49% |
| 2012 Q2 | -26.15 Million USD | -18.69% |
| 2012 Q1 | -22.03 Million USD | -18.25% |
| 2011 FY | -18.63 Million USD | -130.69% |
| 2011 Q3 | -18.54 Million USD | 56.5% |
| 2011 Q4 | -18.63 Million USD | -0.46% |
| 2011 Q2 | -42.63 Million USD | -69.48% |
| 2011 Q1 | -25.15 Million USD | -211.46% |
| 2010 Q1 | -13.76 Million USD | -7.77% |
| 2010 FY | -8.07 Million USD | 36.77% |
| 2010 Q4 | -8.07 Million USD | 61.53% |
| 2010 Q3 | -20.99 Million USD | 32.05% |
| 2010 Q2 | -30.89 Million USD | -124.43% |
| 2009 Q1 | -33.77 Million USD | 20.74% |
| 2009 Q4 | -12.77 Million USD | 86.19% |
| 2009 FY | -12.77 Million USD | 70.03% |
| 2009 Q3 | -92.47 Million USD | -340.76% |
| 2009 Q2 | -20.98 Million USD | 37.88% |
| 2008 Q2 | -47.04 Million USD | 53.38% |
| 2008 Q3 | -55.48 Million USD | -17.93% |
| 2008 Q4 | -42.61 Million USD | 23.2% |
| 2008 Q1 | -100.91 Million USD | -136.18% |
| 2008 FY | -42.61 Million USD | 0.27% |
| 2007 Q4 | -42.72 Million USD | -15.7% |
| 2007 FY | -42.72 Million USD | 5.83% |
| 2007 Q2 | -64.22 Million USD | -57.22% |
| 2007 Q1 | -40.85 Million USD | 9.97% |
| 2007 Q3 | -36.93 Million USD | 42.5% |
| 2006 FY | -45.37 Million USD | 39.16% |
| 2006 Q3 | -52.84 Million USD | 11.08% |
| 2006 Q2 | -59.43 Million USD | 4.94% |
| 2006 Q1 | -62.51 Million USD | 16.17% |
| 2006 Q4 | -45.37 Million USD | 14.13% |
| 2005 FY | -74.57 Million USD | -788.56% |
| 2005 Q4 | -74.57 Million USD | 16.91% |
| 2005 Q3 | -89.75 Million USD | -1014.13% |
| 2005 Q2 | -8.05 Million USD | 21.57% |
| 2005 Q1 | -10.27 Million USD | -22.39% |
| 2004 FY | -8.39 Million USD | -37.01% |
| 2004 Q3 | -3.4 Million USD | 37.03% |
| 2004 Q4 | -8.39 Million USD | -146.2% |
| 2004 Q1 | -39.29 Million USD | -541.4% |
| 2004 Q2 | -5.41 Million USD | 86.22% |
| 2003 Q2 | -53.43 Million USD | -224.15% |
| 2003 Q3 | -20.04 Million USD | 62.49% |
| 2003 Q4 | -6.12 Million USD | 69.43% |
| 2003 Q1 | -16.48 Million USD | 20.88% |
| 2003 FY | -6.12 Million USD | 70.6% |
| 2002 Q2 | -12.9 Million USD | 42.45% |
| 2002 Q4 | -20.83 Million USD | 29.56% |
| 2002 FY | -20.83 Million USD | -411.39% |
| 2002 Q1 | -22.42 Million USD | -450.54% |
| 2002 Q3 | -29.57 Million USD | -129.13% |
| 2001 Q4 | -4.07 Million USD | -30.79% |
| 2001 Q3 | -3.11 Million USD | -238.2% |
| 2001 FY | -4.07 Million USD | 89.79% |
| 2001 Q1 | -12.74 Million USD | 68.07% |
| 2001 Q2 | 2.25 Million USD | 117.69% |
| 2000 Q4 | -39.91 Million USD | 0.0% |
| 2000 FY | -39.91 Million USD | -2295.65% |
| 1999 FY | 1.81 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | -55.94 Million USD | 149.684% |
| Alkermes plc | -166.73 Million USD | 116.669% |
| Agenus Inc. | 274.13 Million USD | 89.862% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 98.514% |
| Aptorum Group Limited | 1.35 Million USD | -1948.051% |
| Ardelyx, Inc. | 34.51 Million USD | 19.469% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | -549.369% |
| Bicycle Therapeutics plc | -481.46 Million USD | 105.773% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | 23.145% |
| ChromaDex Corporation | -24.04 Million USD | 215.573% |
| Chimerix, Inc. | -25.51 Million USD | 208.92% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -298.862% |
| Caribou Biosciences, Inc. | -23.67 Million USD | 217.384% |
| CRISPR Therapeutics AG | -150.84 Million USD | 118.425% |
| Precision BioSciences, Inc. | -85.41 Million USD | 132.541% |
| Dyadic International, Inc. | -6.37 Million USD | 535.757% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | 274.437% |
| Fortress Biotech, Inc. | 7.66 Million USD | -262.596% |
| Lantern Pharma Inc. | -21.7 Million USD | 228.059% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 125.144% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | 425.324% |
| Incyte Corporation | -3.17 Billion USD | 100.875% |
| IO Biotech, Inc. | -140.69 Million USD | 119.754% |
| Jaguar Health, Inc. | 29.39 Million USD | 5.437% |
| Novavax, Inc. | -298.29 Million USD | 109.317% |
| Janux Therapeutics, Inc. | 5.33 Million USD | -420.761% |
| Opthea Limited | 28.15 Million USD | 1.294% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | 265.543% |
| ContextLogic Inc. | -232 Million USD | 111.98% |
| MiMedx Group, Inc. | -33.9 Million USD | 181.983% |
| Pyxis Oncology, Inc. | 10.19 Million USD | -172.614% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | 1299.511% |
| NextCure, Inc. | -6.47 Million USD | 529.103% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 155.035% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | 535.695% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | -128.499% |
| Vaxcyte, Inc. | -368.22 Million USD | 107.548% |
| PDS Biotechnology Corporation | -32.7 Million USD | 184.971% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | -60.858% |
| Pharming Group N.V. | 109.8 Million USD | 74.689% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | 259.767% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 115.861% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 250.071% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 250.071% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 491.451% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | 574.283% |
| Acelyrin, Inc. | -216.9 Million USD | 112.814% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | 595.395% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | 1712.123% |
| Summit Therapeutics Inc. | 34.67 Million USD | 19.845% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | 508.54% |
| Senti Biosciences, Inc. | 1.74 Million USD | -1497.299% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 115.055% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 135.885% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | 558.479% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | -27757.35% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | -4325.637% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 123.745% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 116.521% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 74.932% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 465.89% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 121.526% |
| Psyence Biomedical Ltd. | 6.89 Million USD | -303.113% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 111.468% |
| Immix Biopharma, Inc. | -17.5 Million USD | 258.728% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 108.776% |
| MEI Pharma, Inc. | -3.7 Million USD | 850.148% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | -122.149% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 82.816% |
| Fortress Biotech, Inc. | 7.66 Million USD | -262.596% |
| Precigen, Inc. | -481 Thousand USD | 5878.17% |
| Clearside Biomedical, Inc. | 14.08 Million USD | -97.379% |
| AlloVir, Inc. | -62.69 Million USD | 144.333% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 149.975% |
| Fate Therapeutics, Inc. | 61.66 Million USD | 54.93% |
| ImmuCell Corporation | 10.99 Million USD | -152.881% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 118.03% |
| Onconetix, Inc. | 5.33 Million USD | -421.304% |
| PureTech Health plc | -167.19 Million USD | 116.623% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 191.244% |
| Elevation Oncology, Inc. | -19.11 Million USD | 245.376% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | 666.164% |
| Seer, Inc. | -4.24 Million USD | 755.495% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 215.626% |
| Innoviva, Inc. | 255.56 Million USD | 89.125% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 149.751% |
| ESSA Pharma Inc. | -33.62 Million USD | 182.664% |
| GlycoMimetics, Inc. | -40.98 Million USD | 167.814% |
| GT Biopharma, Inc. | -1.02 Million USD | 2822.135% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 141.003% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | 54.629% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 120.729% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | 300.585% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 196.263% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | 36993.036% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 190.056% |
| Aptose Biosciences Inc. | -8.19 Million USD | 439.152% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | 988.234% |
| Soligenix, Inc. | -4.95 Million USD | 661.294% |
| Century Therapeutics, Inc. | 847 Thousand USD | -3181.346% |
| Kura Oncology, Inc. | -20.11 Million USD | 238.15% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 167.91% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | 430.948% |
| Ocean Biomedical, Inc. | 1.82 Million USD | -1425.667% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | 969.346% |
| Autolus Therapeutics plc | -186.59 Million USD | 114.895% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 156.371% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 110.077% |
| Eterna Therapeutics Inc. | 34.26 Million USD | 18.895% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | 83.091% |
| GRI Bio, Inc. | -1.79 Million USD | 1649.22% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | 409.394% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 183.57% |
| IGM Biosciences, Inc. | -72.6 Million USD | 138.279% |
| INmune Bio, Inc. | -25.41 Million USD | 209.374% |
| Heron Therapeutics, Inc. | 150.95 Million USD | 81.588% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 154.863% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 271.04% |
| Entero Therapeutics, Inc. | -2.88 Million USD | 1063.387% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | 26.889% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 167.483% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 12.834% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 92.646% |
| Verastem, Inc. | -37.27 Million USD | 174.556% |
| Abeona Therapeutics Inc. | -9.07 Million USD | 406.326% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 153.59% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | 283.634% |
| Histogen Inc. | -7.48 Million USD | 471.217% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | 228.631% |
| Surrozen, Inc. | -32.66 Million USD | 185.088% |
| Organovo Holdings, Inc. | -1.5 Million USD | 1944.26% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 761.189% |
| Ovid Therapeutics Inc. | 18.96 Million USD | -46.586% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | -962.424% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | -568.744% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | 431.613% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 163.977% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | 290.665% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 108.773% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | 3949.126% |
| Apollomics, Inc. | -27.39 Million USD | 201.453% |
| Amarin Corporation plc | -191.04 Million USD | 114.548% |
| Mesoblast Limited | 55.96 Million USD | 50.337% |
| Turnstone Biologics Corp. | -14.58 Million USD | 290.572% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 209.889% |
| Synaptogenix, Inc. | -28.66 Million USD | 196.97% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | 3069.338% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | 42.968% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 3323.913% |
| Monopar Therapeutics Inc. | -7.26 Million USD | 482.503% |
| Exelixis, Inc. | -73.05 Million USD | 138.047% |
| Better Therapeutics, Inc. | -860 Thousand USD | 3331.744% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 215.741% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 111.515% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -3675.884% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | 473.655% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -2116.348% |
| Gritstone bio, Inc. | 39.49 Million USD | 29.62% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 133.047% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | 1155.909% |
| Avid Bioservices, Inc. | 169.72 Million USD | 83.625% |
| Insmed Incorporated | 721.62 Million USD | 96.149% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | 404.031% |
| MediWound Ltd. | -5.32 Million USD | 622.228% |
| OmniAb, Inc. | 9.2 Million USD | -201.999% |
| Alector, Inc. | -35.63 Million USD | 177.989% |
| Seres Therapeutics, Inc. | 85.97 Million USD | 67.672% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | 663.981% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | -109.933% |
| Zai Lab Limited | -775 Million USD | 103.586% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 91.839% |
| Aura Biosciences, Inc. | -21.52 Million USD | 229.12% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 133.697% |
| Immunic, Inc. | -45.34 Million USD | 161.299% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 114.384% |
| Veracyte, Inc. | -203.82 Million USD | 113.636% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 95.646% |
| FibroGen, Inc. | 56.76 Million USD | 51.04% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -212.106% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | 1083.098% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | 1442.431% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 99.395% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | 931.877% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 116.746% |
| TG Therapeutics, Inc. | 17.86 Million USD | -55.598% |
| Galecto, Inc. | -21.21 Million USD | 231.0% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 216.851% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 98.229% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 213.571% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | 341.531% |
| XBiotech Inc. | -200.02 Million USD | 113.895% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 133.047% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | -513.803% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 178.816% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 135.993% |
| Theravance Biopharma, Inc. | 5.69 Million USD | -388.368% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 116.309% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 130.087% |
| Vaxxinity, Inc. | 10.13 Million USD | -174.309% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 96.225% |
| Gain Therapeutics, Inc. | -10.76 Million USD | 358.118% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 142.139% |
| NexImmune, Inc. | -3.13 Million USD | 986.923% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | 904.971% |
| Marker Therapeutics, Inc. | -15.11 Million USD | 283.92% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 202.557% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | 409.635% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 22410.255% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 168.503% |
| Ainos, Inc. | 4.07 Million USD | -581.547% |
| Pluri Inc. | 22.82 Million USD | -21.744% |
| Prothena Corporation plc | -608.34 Million USD | 104.569% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 123.403% |
| Celularity Inc. | 65.19 Million USD | 57.366% |
| Rallybio Corporation | -24.1 Million USD | 215.314% |
| Cue Biopharma, Inc. | -33.81 Million USD | 182.182% |
| MeiraGTx Holdings plc | -40.3 Million USD | 168.962% |
| Omeros Corporation | 331.17 Million USD | 91.608% |
| Humacyte, Inc. | -22.48 Million USD | 223.601% |
| Immunocore Holdings plc | -358.59 Million USD | 107.751% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 213.095% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 189.942% |
| Blueprint Medicines Corporation | 702.83 Million USD | 96.046% |
| CalciMedica, Inc. | -5.53 Million USD | 602.586% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 114.766% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | 372.107% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 169.418% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 183.58% |
| Pulmatrix, Inc. | -10.41 Million USD | 366.804% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | 564.999% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 172.867% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 124.948% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 146.365% |
| Cytokinetics, Incorporated | 642.37 Million USD | 95.673% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 577.297% |
| Nutriband Inc. | -251.65 Thousand USD | 11144.0% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 181.459% |
| Vor Biopharma Inc. | 4.3 Million USD | -546.349% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 100.46% |
| Evogene Ltd. | -19.63 Million USD | 241.555% |
| ProKidney Corp. | -56.23 Million USD | 149.422% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 157.103% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | 400.882% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 97.962% |
| CorMedix Inc. | -43.05 Million USD | 164.556% |
| BioLineRx Ltd. | 7.33 Million USD | -278.858% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 201.194% |
| Galectin Therapeutics Inc. | 46.14 Million USD | 39.773% |
| Atai Life Sciences N.V. | -28.55 Million USD | 197.321% |
| Renovaro Biosciences Inc. | 2.23 Million USD | -1146.027% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 221.814% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | -56.713% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 137.021% |
| MediciNova, Inc. | -50.78 Million USD | 154.728% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 135.268% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 123651.9% |
| GeoVax Labs, Inc. | -6.45 Million USD | 530.726% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 113.909% |
| Biomea Fusion, Inc. | -166.57 Million USD | 116.685% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 115.529% |
| Mereo BioPharma Group plc | -51.46 Million USD | 153.999% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 129.304% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 109.461% |
| Absci Corporation | -72.59 Million USD | 138.283% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -508.695% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 111.855% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 129.501% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 129.043% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 171.131% |
| Allakos Inc. | -24.97 Million USD | 211.283% |
| Imunon, Inc. | -4.21 Million USD | 759.563% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | 288.529% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 120.527% |
| BioAtla, Inc. | -109.01 Million USD | 125.496% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -3675.884% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 3059.851% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | -132.266% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | 231.081% |
| XOMA Corporation | -29 Million USD | 195.838% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | 267.832% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 408.263% |
| aTyr Pharma, Inc. | -7.44 Million USD | 473.11% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 122.299% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 113.351% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 133.985% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 129.961% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | 3334.813% |
| Akari Therapeutics, Plc | -3.84 Million USD | 822.835% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -1612.562% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 97.987% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 2439.212% |
| UroGen Pharma Ltd. | 4.39 Million USD | -532.954% |
| Sutro Biopharma, Inc. | 113.48 Million USD | 75.509% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -38521.773% |
| Orgenesis Inc. | 21.78 Million USD | -27.584% |
| Entera Bio Ltd. | -10.62 Million USD | 361.483% |
| GH Research PLC | -78.07 Million USD | 135.597% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | 224.699% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 204.254% |
| Xencor, Inc. | 29.64 Million USD | 6.244% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | 1510.947% |
| Replimune Group, Inc. | 1.41 Million USD | -1868.343% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | 11448.343% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 121.985% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 2439.212% |
| Portage Biotech Inc. | -4.98 Million USD | 657.98% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 123651.9% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 142.033% |
| OncoCyte Corporation | -6.56 Million USD | 523.48% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | -2997.013% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | 710.079% |
| Purple Biotech Ltd. | -14.13 Million USD | 296.584% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 216.994% |
| scPharmaceuticals Inc. | -6.54 Million USD | 524.645% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | 266.503% |
| HilleVax, Inc. | -165.48 Million USD | 116.795% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | 1195.075% |
| Tharimmune, Inc. | -10.93 Million USD | 354.157% |
| Genprex, Inc. | -6.73 Million USD | 512.504% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 107.536% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 131.419% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | 2083.797% |
| Virios Therapeutics, Inc. | -3.31 Million USD | 937.909% |
| OKYO Pharma Limited | -826.84 Thousand USD | 3461.319% |
| Savara Inc. | 153 Thousand USD | -18065.359% |
| Curis, Inc. | -23.88 Million USD | 216.352% |
| Daré Bioscience, Inc. | -5.15 Million USD | 638.842% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | 3681.517% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | 547.697% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | -2245.401% |
| BeiGene, Ltd. | -2.25 Billion USD | 101.234% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | -125.254% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 104.57% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 114.976% |
| Erasca, Inc. | -37.21 Million USD | 174.68% |
| bluebird bio, Inc. | 108.57 Million USD | 74.401% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 2258.021% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 92.662% |
| DBV Technologies S.A. | -126.98 Million USD | 121.887% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 2258.021% |
| Moderna, Inc. | -2.9 Billion USD | 100.956% |
| Vincerx Pharma, Inc. | -10.35 Million USD | 368.48% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | 355.732% |
| Molecular Templates, Inc. | 707 Thousand USD | -3831.117% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 188.595% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 91.981% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 133.868% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 130.299% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 186.121% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 180.85% |
| MacroGenics, Inc. | -66.98 Million USD | 141.491% |
| RenovoRx, Inc. | -1.17 Million USD | 2469.395% |
| Adicet Bio, Inc. | -138.78 Million USD | 120.026% |
| Prime Medicine, Inc. | -27.94 Million USD | 199.47% |
| Aditxt, Inc. | 18.12 Million USD | -53.376% |
| Adagene Inc. | -87.62 Million USD | 131.717% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 767.23% |
| Quantum-Si incorporated | -118.55 Million USD | 123.443% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | 22.808% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | 471.853% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 157.295% |
| SciSparc Ltd. | -2.06 Million USD | 1445.908% |
| Vericel Corporation | 1.27 Million USD | -2076.429% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 331.769% |
| Minerva Neurosciences, Inc. | 41 Million USD | 32.219% |
| Generation Bio Co. | 31.44 Million USD | 11.622% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 115.849% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 189.878% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | 76.162% |
| Invivyd, Inc. | -198.47 Million USD | 114.003% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 130.789% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | 1259.158% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 139.261% |
| Artelo Biosciences, Inc. | -6.82 Million USD | 507.223% |
| 2seventy bio, Inc. | 181.71 Million USD | 84.705% |
| ADMA Biologics, Inc. | 90.06 Million USD | 69.142% |
| Clene Inc. | 3.34 Million USD | -732.126% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | 405.999% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | 229.204% |
| GeoVax Labs, Inc. | -6.45 Million USD | 530.726% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 108.076% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 206.897% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | 84.357% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | 779.275% |
| Finch Therapeutics Group, Inc. | 5 Million USD | -455.638% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | 633.557% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 121.329% |
| Evaxion Biotech A/S | 5.28 Million USD | -425.701% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 124.69% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 121.172% |
| Trevena, Inc. | 2.25 Million USD | -1130.868% |
| Surrozen, Inc. | -32.66 Million USD | 185.088% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 153.957% |
| Cingulate Inc. | 3.08 Million USD | -801.585% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | 1046.306% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -286.712% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | 399.132% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 135.038% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 121.143% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 126.334% |
| Clearmind Medicine Inc. | -3.94 Million USD | 804.934% |
| Kronos Bio, Inc. | -36.05 Million USD | 177.087% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | -195.387% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -1806.075% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 151.226% |
| Statera Biopharma, Inc. | 14.41 Million USD | -92.787% |
| ImmunityBio, Inc. | 618.22 Million USD | 95.504% |
| Korro Bio, Inc. | -132.94 Million USD | 120.906% |
| Kineta, Inc. | -4.54 Million USD | 712.046% |
| BioVie Inc. | -17.73 Million USD | 256.736% |
| Codexis, Inc. | -43.27 Million USD | 164.23% |
| Celularity Inc. | 65.19 Million USD | 57.366% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | 977.027% |
| Celcuity Inc. | 6.78 Million USD | -309.714% |
| Virax Biolabs Group Limited | -3.36 Million USD | 925.957% |
| Cibus, Inc. | -8.07 Million USD | 444.058% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | 757.2% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | -508.162% |
| IN8bio, Inc. | -16.38 Million USD | 269.583% |
| Kodiak Sciences Inc. | -103.87 Million USD | 126.756% |
| Annexon, Inc. | -193.75 Million USD | 114.344% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | -77102.778% |
| Assembly Biosciences, Inc. | -17.49 Million USD | 258.826% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | 891.147% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 97.364% |
| Eyenovia, Inc. | 1.25 Million USD | -2108.068% |
| Puma Biotechnology, Inc. | 26.9 Million USD | -3.301% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 957.015% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 183.596% |
| Arcellx, Inc. | -296.95 Million USD | 109.359% |
| Cardiff Oncology, Inc. | -19.5 Million USD | 242.484% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 147.207% |
| Regulus Therapeutics Inc. | -20.72 Million USD | 234.091% |
| Moolec Science SA | 117.61 Thousand USD | -23530.288% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 172.379% |
| Geron Corporation | 14.76 Million USD | -88.287% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 173.298% |
| Royalty Pharma plc | 5.65 Billion USD | 99.509% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 119.653% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | 497.644% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | 618.25% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 119.749% |
| Humacyte, Inc. | -22.48 Million USD | 223.601% |
| Structure Therapeutics Inc. | -124.33 Million USD | 122.353% |
| 89bio, Inc. | -289.05 Million USD | 109.615% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 210.106% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | 1658.777% |
| Genelux Corporation | -6.89 Million USD | 502.855% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 189.485% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | 66.754% |
| Notable Labs, Ltd. | -9.77 Million USD | 384.298% |
| Liquidia Corporation | -80.17 Million USD | 134.665% |
| Mustang Bio, Inc. | -3.73 Million USD | 843.924% |
| Immunovant, Inc. | -635.22 Million USD | 104.375% |
| Quantum-Si incorporated | -118.55 Million USD | 123.443% |
| Arbutus Biopharma Corporation | -17.56 Million USD | 258.238% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | 770.842% |
| Vera Therapeutics, Inc. | 8.02 Million USD | -246.244% |
| Acasti Pharma Inc. | -23 Million USD | 220.813% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | 925.397% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 271.04% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 120.178% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | 991.841% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | 225.013% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | 249.674% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 116.419% |
| PepGen Inc. | -60.67 Million USD | 145.81% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 220.965% |
| United Therapeutics Corporation | -507.7 Million USD | 105.474% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | 245.315% |
| Solid Biosciences Inc. | -47.75 Million USD | 158.205% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 3323.913% |
| Immuneering Corporation | -54.94 Million USD | 150.585% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 761.189% |
| Silo Pharma, Inc. | -3.52 Million USD | 888.609% |
| Belite Bio, Inc | -87.27 Million USD | 131.847% |
| XOMA Corporation | -29 Million USD | 195.838% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 139.313% |
| Bionomics Limited | 227 Million USD | 87.757% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 123.901% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 1197.236% |
| uniQure N.V. | -102.95 Million USD | 126.996% |
| Cassava Sciences, Inc. | -121.13 Million USD | 122.944% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 767.23% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | 32.131% |
| Forte Biosciences, Inc. | -11.96 Million USD | 332.364% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | 998.229% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | -26119.811% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 957.015% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -212.106% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | 474.771% |
| Altimmune, Inc. | -134.48 Million USD | 120.666% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 85.968% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 1197.236% |
| Compugen Ltd. | -12.9 Million USD | 315.383% |
| Peak Bio, Inc. | 10.34 Million USD | -168.787% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | 9920.848% |
| Benitec Biopharma Inc. | -50.58 Million USD | 154.946% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 126.637% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | -41.476% |
| Zura Bio Limited | -99.8 Million USD | 127.847% |
| PolyPid Ltd. | 6.17 Million USD | -350.454% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | 62.503% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | -41.476% |
| Instil Bio, Inc. | 75.35 Million USD | 63.119% |
| argenx SE | -2.02 Billion USD | 101.37% |
| Immunome, Inc. | -97.02 Million USD | 128.644% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 223.552% |
| Verona Pharma plc | -220.44 Million USD | 112.608% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 138.74% |
| Shattuck Labs, Inc. | -121.42 Million USD | 122.889% |
| CervoMed Inc. | -7.79 Million USD | 456.648% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 114.983% |
| Plus Therapeutics, Inc. | -4.37 Million USD | 735.559% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 121.097% |
| Moolec Science SA | 117.61 Thousand USD | -23530.288% |
| Enveric Biosciences, Inc. | -2.28 Million USD | 1314.741% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | -74.817% |
| AnaptysBio, Inc. | -18.15 Million USD | 253.121% |
| Design Therapeutics, Inc. | -18.15 Million USD | 253.129% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 139.489% |
| NeurAxis, Inc. | 145.7 Thousand USD | -18975.498% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | -147.445% |
| Lumos Pharma, Inc. | -28.49 Million USD | 197.543% |
| Achilles Therapeutics plc | -126.92 Million USD | 121.897% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 138.74% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | 4338.482% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | 233.789% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -1806.075% |
| Nutriband Inc. | -251.65 Thousand USD | 11144.0% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | 311.017% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | 473.562% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 91.83% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | -17.097% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 106.211% |
| Palisade Bio, Inc. | -12.06 Million USD | 330.399% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 119.808% |
| Beam Therapeutics Inc. | -262.72 Million USD | 110.579% |
| Neurogene Inc. | -131.95 Million USD | 121.062% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | -27.397% |
| AEON Biopharma, Inc. | -4.88 Million USD | 669.529% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 107.368% |
| Sesen Bio, Inc. | -112.55 Million USD | 124.693% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 127.832% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | 1283.793% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 171.217% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 133.372% |
| Athira Pharma, Inc. | -88.99 Million USD | 131.228% |
| Vaccinex, Inc. | -1.28 Million USD | 2257.842% |
| HCW Biologics Inc. | 2.85 Million USD | -872.914% |
| XOMA Corporation | -29 Million USD | 195.838% |
| Nektar Therapeutics | 210.24 Million USD | 86.78% |
| Arvinas, Inc. | -313.8 Million USD | 108.857% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -1612.562% |
| Merus N.V. | -192.88 Million USD | 114.409% |
| Omega Therapeutics, Inc. | 59.98 Million USD | 53.667% |
| Quince Therapeutics, Inc. | -6.93 Million USD | 500.591% |
| Rezolute, Inc. | -68.16 Million USD | 140.771% |
| Clene Inc. | 3.34 Million USD | -732.126% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | 310.761% |
| BeyondSpring Inc. | -13.75 Million USD | 302.057% |
| Synlogic, Inc. | -6.68 Million USD | 515.752% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | -2350.882% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | 428.717% |
| Peak Bio, Inc. | 10.34 Million USD | -168.787% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 133.721% |
| Krystal Biotech, Inc. | -350.23 Million USD | 107.936% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | 77.609% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 116.446% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | 980.321% |
| MannKind Corporation | 143.89 Million USD | 80.686% |
| Ikena Oncology, Inc. | -109.15 Million USD | 125.462% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | 467.098% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 183.967% |
| Gossamer Bio, Inc. | 180.35 Million USD | 84.59% |
| CohBar, Inc. | -5.93 Million USD | 568.627% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 193.428% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -508.695% |
| Legend Biotech Corporation | -949.39 Million USD | 102.927% |
| Mural Oncology plc | -255.84 Million USD | 110.863% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 13.727% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 690.005% |
| Disc Medicine, Inc. | -358.28 Million USD | 107.757% |
| Champions Oncology, Inc. | 4.81 Million USD | -477.577% |
| REGENXBIO Inc. | 54.76 Million USD | 49.253% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | 10435.544% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 118.403% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | 408.4% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 134.447% |
| Vaxart, Inc. | -8.24 Million USD | 437.253% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 155.387% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 121.856% |
| Cellectis S.A. | -43.85 Million USD | 163.375% |
| Longeveron Inc. | -2.9 Million USD | 1055.743% |
| Repare Therapeutics Inc. | -107.85 Million USD | 125.768% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 97.13% |
| Inozyme Pharma, Inc. | 12 Million USD | -131.531% |
| Revolution Medicines, Inc. | -608.2 Million USD | 104.57% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | 2359.593% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 110.483% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 118.52% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | 277.625% |
| Anixa Biosciences, Inc. | -740 Thousand USD | 3855.811% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 100.291% |
| Denali Therapeutics Inc. | -74.86 Million USD | 137.124% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 331.769% |
| Veru Inc. | 4.77 Million USD | -481.447% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | 347.137% |
| Cingulate Inc. | 3.08 Million USD | -801.585% |
| Passage Bio, Inc. | 4.58 Million USD | -506.172% |
| Context Therapeutics Inc. | -14.44 Million USD | 292.341% |
| Exicure, Inc. | 5.84 Million USD | -375.175% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 112.064% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 170.238% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | -77.127% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 147.25% |
| Nuvalent, Inc. | -335.38 Million USD | 108.287% |
| ABVC BioPharma, Inc. | 1.73 Million USD | -1502.511% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 137.315% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | 412.632% |
| OmniAb, Inc. | 9.2 Million USD | -201.999% |
| Anew Medical, Inc. | 1.43 Million USD | -1840.222% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | -69.658% |
| Lipocine Inc. | -4.75 Million USD | 684.551% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 125.306% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | -82.477% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 154.863% |
| G1 Therapeutics, Inc. | 24.89 Million USD | -11.654% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | 513.525% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 142.221% |
| Ocugen, Inc. | -32.52 Million USD | 185.462% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 132.478% |
| Q32 Bio Inc. | -37.94 Million USD | 173.24% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | 4525.637% |
| Alumis Inc. Common Stock | -13.52 Million USD | 305.433% |
| Equillium, Inc. | -22.39 Million USD | 224.12% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 208.702% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 185.185% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | 11310.697% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 79.265% |
| Evelo Biosciences, Inc. | 3.19 Million USD | -769.074% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -8362.098% |
| Dominari Holdings Inc. | 195 Thousand USD | -14152.821% |
| Edesa Biotech, Inc. | -5.26 Million USD | 627.691% |
| vTv Therapeutics Inc. | -8.91 Million USD | 411.686% |
| Bio-Techne Corporation | 267.74 Million USD | 89.62% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | 271.466% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 123.535% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | 430.751% |
| Candel Therapeutics, Inc. | -12.65 Million USD | 319.69% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 111.339% |
| Nkarta, Inc. | 57.29 Million USD | 51.495% |
| BioCardia, Inc. | 212 Thousand USD | -13009.906% |
| Iterum Therapeutics plc | 13.43 Million USD | -106.824% |